Physician profile
Mauricio Zapiach
NPI 1831260777
$3,644.46
in general payments reported to CMS, 2019-2025
21 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $816 · 2021: $510 · 2022: $630 · 2023: $151 · 2024: $266 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616 · Education: $79.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.47 |
| Education | $79.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $805.60 | 2019-2024 | Xifaxan |
| Abbvie INC. | $615.48 | 2019-2023 | Viberzi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $348.45 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $282.73 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Madrigal Pharmaceuticals | $282.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $206.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $197.23 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $143.49 | 2019-2021 | |
| Redhill Biopharma INC. | $121.74 | 2020-2023 | |
| Janssen Scientific Affairs, LLC | $111.75 | 2019 | |
| Allergan, INC. | $106.04 | 2019-2020 | |
| Celgene Corporation | $75.29 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $74.10 | 2020-2025 | Suflave |
| Ironwood Pharmaceuticals, INC | $60.83 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $59.18 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.50 | 2024-2025 | Voquezna |
| Ucb, INC. | $35.26 | 2019 | |
| Ardelyx, INC. | $25.24 | 2025 | Ibsrela |
| Genzyme Corporation | $19.53 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.87 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Zapiach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.